ProKidney Corp. (PROK NASDAQ) stock market data APIs
$2.0455
-0.15(-7.3%)
as of July 2, 2026
Try our APIs with
free plan!
ProKidney Corp. Financial Data Overview
Price chart is built with
Anychart
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Prev. Close
2.0455
Open
1.8972
High
2.1
Low
1.8713
52 wk Range
0.5916-7.13
Market Cap
613 M
Shares Outstanding
205 M
Revenue
889 K
EPS
-0.14
Beta
1.7
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ProKidney Corp. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ProKidney Corp. data using free add-ons & libraries
Get ProKidney Corp. Fundamental Data
ProKidney Corp. Fundamental data includes:
- Net Revenue: 889 K
- EBITDA: -161 919 008
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-15
- EPS/Forecast: -0.1375
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ProKidney Corp. News
New
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
ProKidney Corp. (NASDAQ:PROK) is one of the small-cap stocks with potential to rise 1000 percent. The company's main story centers on rilparencel, its experimental cell therapy for patients with advan...
Identiv And Two Other Penny Stocks To Watch Closely
The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 16% annually. For investors willing to look beyond the big names, penny stocks can p...
ProKidney Appoints Kenneth Locke as Chief Technical Officer
ProKidney Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward ...
ProKidney GAAP EPS of -$0.14 beats by $0.01, revenue of $0.23M beats by $0.03M
* ProKidney press release [https://seekingalpha.com/pr/20517549-prokidney-reports-first-quarter-2026-financial-results-and-business-highlights] (PROK [https://seekingalpha.com/symbol/PROK]): Q1 GAAP...
Get ProKidney Corp. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
